No. of patients who received thrombolysis or endovascular therapy | 2853 | 147 | 163 | 144 | 228 | 61 |
Prehospital response time |
Onset-to-door, min, median (IQR) | 84 (52–152) | 84 (53–161) | 101 (59–170) | 81 (48–185) | 82 (56–172) | 93 (56–157) |
Unadjusted difference (95% CI) | Ref. | −1.00 (−16.2 to 14.2) | 16.0 (1.5 to 30.5) | −4.0 (−19.2 to 11.2) | −2.5 (−13.3 to 11.3) | 8.0 (−15.0 to 31.0) |
Adjusted difference† (95% CI) | Ref. | −5.0 (−20.2 to 10.3) | 24.3 (9.1 to 39.4) | −5.9 (−19.7 to 7.9) | 2.3 (−8.9 to 13.5) | 5.1 (−15.7 to 25.9) |
In-hospital workflow times |
Door-to-CT, min, median (IQR) | 18 (12–28) | 18 (13–29) | 19 (12–24) | 17 (13–24) | 16 (11–21) | 17 (13–24) |
Unadjusted difference (95% CI) | Ref. | 0.0 (−2.5 to 2.5) | 1.0 (−2.5 to 2.5) | −1.0 (−3.5 to 1.5) | −2.0 (−4.0 to −0.02) | −1.0 (−4.7 to 2.7) |
Adjusted difference† (95% CI) | Ref. | −0.3 (−2.7 to 2.0) | 0.1 (−2.3 to 2.4) | −0.3 (−2.4 to 1.8) | −1.8 (−3.5 to −0.05) | −0.8 (−4.0 to 2.4) |
Door-to-needle (thrombolysis), min, median (IQR) | 43 (30–66) | 46 (32–70) | 42 (34–61) | 43 (30–65) | 46 (33–64) | 42 (32–60) |
Unadjusted difference (95% CI) | Ref. | 4.0 (−1.4 to 9.4) | 0.5 (−5.3 to 5.3) | 0.0 (−5.4 to 5.4) | 3.0 (−1.5 to 7.5) | 0.5 (−7.8 to 7.8) |
Adjusted difference† (95% CI) | Ref. | 4.9 (−1.1 to 10.9) | 0.2 (−5.9 to 6.3) | 1.5 (−3.9 to 7.0) | 4.2 (−0.3 to 8.7) | 1.4 (−6.4 to 9.2) |
CT-to-groin puncture (endovascular therapy), min, median (IQR) | 53 (35–79) | 78 (40–114) | 63 (46–106) | 58 (43–79) | 66 (46–90) | 43 (33–90) |
Unadjusted difference (95% CI) | Ref. | 26.0 (13.9 to 38.1) | 11.0 (−0.1 to 22.1) | 6.0 (−6.0 to 18.0) | 14.0 (4.8 to 23.2) | −9.0 (−30.8 to 12.8) |
Adjusted difference† (95% CI) | Ref. | 28.2 (15.5 to 41.0) | 6.8 (−5.0 to 18.6) | 5.7 (−6.9 to 18.3) | 13.8 (4.1 to 23.4) | −8.7 (−31.5 to 14.0) |
Door-to-groin puncture (endovascular therapy), min, median (IQR) | 76 (53–110) | 106 (63–141) | 87 (65–135) | 80 (59–102) | 85 (58–113) | 62 (50–115) |
Unadjusted difference (95% CI) | Ref. | 31.0 (15.1 to 46.9) | 12.0 (−2.7 to 26.7) | 4.0 (−11.9 to 19.9) | 10.0 (−2.1 to 22.1) | −14.0 (−42.8 to 14.8) |
Adjusted difference† (95% CI) | Ref. | 24.1 (7.6 to 40.70) | 9.0 (−7.1 to 25.2) | 7.0 (−8.1 to 22.0) | 13.8 (2.2 to 25.3) | −8.6 (−35.7 to 18.5) |
Groin puncture-to-reperfusion (endovascular therapy), min, median (IQR) | 28 (18–44) | 42 (24–61) | 46 (31–61) | 30 (20–52) | 37.5 (24–60) | 29 (21–46) |
Unadjusted difference (95% CI) | Ref. | 14.0 (6.0 to 22.0) | 18.0 (10.6 to 25.4) | 2.0 (−7.0 to 11.0) | 10.0 (3.3 to 16.7) | 1.0 (−13.0 to 15.0) |
Adjusted difference† (95% CI) | Ref. | 13.9 (6.2 to 21.7) | 17.7 (9.7 to 25.8) | 2.1 (−6.6 to 10.7) | 8.1 (1.7 to 14.4) | −2.7 (−16.0 to 10.6) |
Door-to-reperfusion (endovascular therapy), min, median (IQR) | 111 (77–159) | 159 (107–193) | 137 (103–181) | 111.5 (89–144) | 126 (100–160) | 91 (76–150) |
Unadjusted difference (95% CI) | Ref. | 48.0 (24.2 to 71.8) | 26.0 (4.2 to 47.8) | 0.5 (−25.8 to 27.8) | 16.0 (−3.9 to 35.9) | −20.0 (−61.5 to 21.5) |
Adjusted difference† (95% CI) | Ref. | 29.1 (3.5 to 54.7) | 29.2 (4.6 to 53.7) | −0.5 (−27.2 to 26.2) | 14.1 (−5.7 to 33.8) | −10.7 (−51.8 to 30.5) |
Stroke severity score‡ |
Pretreatment (all), points, median (IQR) | 11 (6–18) | 9 (6–16) | 11.5 (6–17) | 10 (5–17) | 12 (7–19) | 9 (5–17) |
Unadjusted difference (95% CI) | Ref. | −1.0 (−2.9 to 0.9) | 0.5 (−0.8 to 2.8) | 0.5 (−1.9 to 1.9) | 2.0 (0.4 to 3.6) | −1.0 (−3.9 to 1.9) |
Adjusted difference† (95% CI) | Ref. | −1.9 (−4.0 to 0.3) | 0.1 (−2.0 to 2.2) | −0.3 (−2.3 to 1.6) | 0.8 (−0.8 to 2.4) | −0.9 (−3.8 to 2.0) |
Thrombolysis recipients, points, median (IQR) | 9 (5–16) | 8 (6–14) | 10 (5–15) | 10 (5–16) | 10 (6–18) | 8 (5–17) |
Unadjusted difference (95% CI) | Ref. | −1.0 (−2.9 to 0.9) | 1.0 (−0.9 to 2.9) | 1.0 (−1.0 to 3.0) | 1.0 (−0.6 to 2.6) | −1.0 (−3.8 to 1.8) |
Adjusted difference† (95% CI) | Ref. | −0.3 (−2.4 to 1.8) | 0.2 (−2.0 to 2.3) | −0.3 (−2.2 to 1.6) | 0.8 (−0.7 to 2.4) | −1.2 (−3.9 to 1.6) |
Endovascular therapy recipients, points, median (IQR) | 16 (11–20) | 13 (9–18) | 15 (8–18) | 16.5 (10–20) | 16 (11–21) | 17 (11–21) |
Unadjusted difference (95% CI) | Ref. | −3.0 (−5.2 to −0.8) | −1.0 (−3.0 to 1.0) | 0.5 (−2.2 to 2.2) | 0.0 (−1.7 to 1.7) | 1.0 (−3.0 to 5.0) |
Adjusted difference† (95% CI) | Ref. | −4.2 (−6.9 to −1.6) | −1.6 (−4.2 to 0.9) | −0.9 (−3.4 to 1.5) | −0.4 (−2.3 to 1.4) | 0.2 (−4.2 to 4.6) |
24 hr after treatment, points, median (IQR) | 3 (1–9) | 3 (0–7) | 3 (1–13) | 2.5 (1–6) | 3 (1–10) | 2 (1–6) |
Unadjusted difference (95% CI) | Ref. | 0.0 (−1.9 to 1.9) | 0.0 (−1.7 to 1.7) | −0.5 (−1.9 to 1.9) | 0.0 (−1.5 to 1.5) | −1.0 (−3.8 to 1.8) |
Adjusted difference† (95% CI) | Ref. | −0.9 (−2.6 to 0.7) | −0.03 (−1.5 to 1.5) | −1.2 (−2.6 to 0.3) | 0.03 (−1.1 to 1.2) | −1.1 (−3.2 to 1.0) |